Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) Return on Capital Employed (2016 - 2025)

Amicus Therapeutics filings provide 15 years of Return on Capital Employed readings, the most recent being 4.88% for Q4 2025.

  • On a quarterly basis, Return on Capital Employed rose 98.0% to 4.88% in Q4 2025 year-over-year; TTM through Dec 2025 was 4.88%, a 98.0% increase, with the full-year FY2025 number at 5.21%, up 128.0% from a year prior.
  • Return on Capital Employed hit 4.88% in Q4 2025 for Amicus Therapeutics, down from 5.1% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 7.04% in Q1 2025 to a low of 39.31% in Q3 2022.
  • Median Return on Capital Employed over the past 5 years was 21.96% (2023), compared with a mean of 16.81%.
  • Biggest five-year swings in Return on Capital Employed: crashed -1279bps in 2022 and later soared 2239bps in 2023.
  • Amicus Therapeutics' Return on Capital Employed stood at 26.3% in 2021, then plummeted by -34bps to 35.19% in 2022, then surged by 64bps to 12.8% in 2023, then skyrocketed by 131bps to 3.9% in 2024, then rose by 25bps to 4.88% in 2025.
  • The last three reported values for Return on Capital Employed were 4.88% (Q4 2025), 5.1% (Q3 2025), and 3.18% (Q2 2025) per Business Quant data.